Helius Medical Technologies (HSDT) Cut to Sell at ValuEngine
Helius Medical Technologies (OTCMKTS:HSDT) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.
Helius Medical Technologies (OTCMKTS:HSDT) traded down $0.05 during trading hours on Friday, reaching $2.23. 16,045 shares of the company were exchanged, compared to its average volume of 90,611. Helius Medical Technologies has a 1-year low of $1.29 and a 1-year high of $4.14.
In other news, Director Blane Walter bought 40,000 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were purchased at an average cost of $2.46 per share, with a total value of $98,400.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Dane Andreeff bought 167,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was purchased at an average cost of $2.58 per share, for a total transaction of $430,860.00. The disclosure for this purchase can be found here. 39.70% of the stock is currently owned by company insiders.
About Helius Medical Technologies
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
Receive News & Stock Ratings for Helius Medical Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies Inc. and related stocks with our FREE daily email newsletter.